Testing New Biomarkers to Help Find and Track Stroke Caused by Blocked Blood Flow
Studies blood and other body samples from adults with ischemic cerebrovascular disease and healthy people.
Plain-language title generated from the registry record
Registry title: Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease
Key facts
- Where
- Wuhan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06890702, who can take part
Where in China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tongji Hospital
- Trial code
- NCT06890702
- Record updated
- 28 July 2026
- Original description
The goal of this single-center prospective observational study is to identify and evaluate new biomarkers for ischemic cerebrovascular disease (ICVD) to aid in early diagnosis, individualized treatment planning, and prognosis prediction in affected patients. The main questions it aims to answer are:Read full original descriptionShow less
A Prospective Observational Cohort Study of Predictive Biomarkers Related With Ischemic Cerebrovascular Disease
The goal of this single-center prospective observational study is to identify and evaluate new biomarkers for ischemic cerebrovascular disease (ICVD) to aid in early diagnosis, individualized treatment planning, and prognosis prediction in affected patients. The main questions it aims to answer are:
Can specific biomarkers help in identifying high-risk individuals before disease onset? Can these biomarkers predict disease progression and treatment response? Researchers will compare patients diagnosed with ICVD and healthy controls from a medical check-up center to assess differences in biomarker expression and their clinical significance.
Participants will:
Provide blood, cerebrospinal fluid, urine, and stool samples for biomarker analysis.
Undergo clinical imaging (CT, MRI, PET-CT) and functional assessments. Be followed up at 3, 6, 12, 24, 36, and 48 months for clinical outcomes and biomarker changes.
This study aims to develop a comprehensive biomarker-based prediction model to enhance the diagnosis and management of ischemic cerebrovascular disease.
Inclusion: Ischemic cerebrovascular disease has been proved by clinical symptoms and imaging examinations,including transient ischemic attack, cerebral ischemic stroke, steal syndrome, chronic cerebral hypoperfusion, ect al; sex and age-matched healthy individuals.
Exclusion: Brain CT or MRI showing cerebral hemorrhage (excluded ischemic stroke with hemorrhage transformation); With severe systemic disease, are expected to survive < 3 months; Patients will not able to provide continuous follow-up information.